SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-21-011512
Filing Date
2021-01-19
Accepted
2021-01-19 16:33:27
Documents
2
Group Members
ANSBERT GADICKEMPM ONCOLOGY IMPACT MANAGEMENT GP LLCMPM ONCOLOGY IMPACT MANAGEMENT LPONCOLOGY IMPACT FUND (CAYMAN) LP

Document Format Files

Seq Description Document Type Size
1 SC 13D d36416dsc13d.htm SC 13D 129881
2 EX-99.C d36416dex99c.htm EX-99.C 9642
  Complete submission text file 0001193125-21-011512.txt   141263
Mailing Address 450 KENDALL STREET CAMBRIDGE MA 02142
Business Address 450 KENDALL STREET CAMBRIDGE MA 02142 617-425-9200
UBS Oncology Impact Fund L.P. (Filed by) CIK: 0001691428 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D

Mailing Address ONE MAIN STREET SUITE 520 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 520 CAMBRIDGE MA 02142 617-410-4650
Cullinan Management, Inc. (Subject) CIK: 0001789972 (see all company filings)

IRS No.: 813867811 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91966 | Film No.: 21535934
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences